Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + DA-EPOCH-R in Pediatric PMLBL
NCT06871007Phase 2Enrolling by invitation
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Sep 2024
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by First Saint Petersburg State Medical University. Started Sep 2024; status: enrolling by invitation.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT06871007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871007.